A Day Of Reckoning for Aging Facilities: Is It Time To Invest In Change?
This article was originally published in Scrip
With its acquisition of Hospira, Pfizer joins those struggling to eke out a profit from aging sterile injectables facilities without shutting them down for badly needed upgrades. Meanwhile, flexible, modular next-generation facilities are looming. Bowman Cox, editor of "The Gold Sheet" looks at the possibilities for the industry's golden oldies.
You may also be interested in...
Alkermes CRL is just the latest fallout from black-hole process.
Letter of authorization for COVID-19 therapeutic made at troubled Lilly plant requires independent third-party oversight.
Prospective new participants in benchmarking study must share manufacturing plant data by 20 November to see how they measure on quality against industry peers.